AstraZeneca Chief Financial Officer Aradhana Sarin says the company is "very much on track" to reach its $80 billion sales target by 2030. "From a pharma standpoint, we are probably one of the most diversified from a product and pipeline, as well as probably the most diversified geographically," Sarin says. She speaks on Bloomberg Television as the company reported higher-than-expected profit, buoyed by blockbuster cancer medicines.